
RAMUCIRUMAB 500 mg/50 mL Injection is a prescription targeted anticancer medication used to treat several advanced cancers, including gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and colorectal cancer. It is a monoclonal antibody administered as an intravenous (IV) infusion under the supervision of an oncology specialist.
| Generic name | RAMUCIRUMAB |
| Strength | 500 mg |
| Manufacturer | Eli Lilly and Company |
| Package size | 1 Vial |
| Used for | Gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and colorectal cancer |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, UAE, Georgia, Armenia, Saudi Arabia, Qatar, Kuwait, South Africa, and many other countries. |
Ramucirumab 500 mg is a monoclonal antibody that blocks the vascular endothelial growth factor receptor-2 (VEGFR-2). By preventing this receptor from being activated, it inhibits the formation of new blood vessels that supply oxygen and nutrients to tumors, helping slow cancer growth and spread.
Dr. Neeru Mehta holds a Doctor of Medicine (MD) degree and has a professional interest in oncology and cancer care. Her interests include cancer treatments, monitoring treatment progress, managing side effects and supportive care.